Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

Leukotrap - CP2D Solution

×

Overview

What is Leukotrap - CP2D Solution?

For collection of blood and preparation of red blood cells, plasma and platelets with pre-storage leukocyte reduction.

Instruction for Use for Systems Containing a Y Sampling Site (YSS) or Sample Diversion Pouch (with or without a pre-attached SampLok™ Vacuum Tube Holder).

Refer to unit foil package label for specific product description being used.

Sterile, non-pyrogenic fluid path. Sterilized by steam.

Rx only.



What does Leukotrap - CP2D Solution look like?



What are the available doses of Leukotrap - CP2D Solution?

Sorry No records found.

What should I talk to my health care provider before I take Leukotrap - CP2D Solution?

Sorry No records found

How should I use Leukotrap - CP2D Solution?

Whole blood; for use in blood collection.


What interacts with Leukotrap - CP2D Solution?

None known.



What are the warnings of Leukotrap - CP2D Solution?

Array


What are the precautions of Leukotrap - CP2D Solution?

Sorry No Records found


What are the side effects of Leukotrap - CP2D Solution?

No adverse reactions specifically attributable to this drug have been reported.


What should I look out for while using Leukotrap - CP2D Solution?

None known.

Failure to achieve and maintain a closed system during processing would result in a product that must be transfused within 24 hours.


What might happen if I take too much Leukotrap - CP2D Solution?

Sorry No Records found


How should I store and handle Leukotrap - CP2D Solution?

* During processing, always observe the following precautions:1. Sealing should be done in a manner that avoids fluid splatter.2. Always dispose of blood-contaminated products in a manner consistent with established BIOHAZARD safety procedures* During processing, always observe the following precautions:1. Sealing should be done in a manner that avoids fluid splatter.2. Always dispose of blood-contaminated products in a manner consistent with established BIOHAZARD safety procedures* During processing, always observe the following precautions:1. Sealing should be done in a manner that avoids fluid splatter.2. Always dispose of blood-contaminated products in a manner consistent with established BIOHAZARD safety procedures


×

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

Collection system with sample diversion pouch

Non-Clinical Toxicology
None known.

Failure to achieve and maintain a closed system during processing would result in a product that must be transfused within 24 hours.

Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.

Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracyclines in conjunction with penicillin.

Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.

Absorption of tetracycline is impaired by bismuth subsalicylate.

Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline.

The concurrent use of tetracycline and Penthrane® (methoxyflurane) has been reported to result in fatal renal toxicity.

Concurrent use of tetracycline may render oral contraceptives less effective.

Use aseptic technique.

Use only if solutions are clear.

Maximum hard spin conditions for RCM1 filter should not exceed 5000 g.

If using centrifuge cups with filter adapters, the RCM1 filter should not be placed within the adapter when hard spin conditions are used.

Do not exceed maximum head heights as indicated within the processing instructions.

Filtration can begin at room temperature up to 8 hours, or 1—6 °C up to 24 hours post-collection. Filtration must begin within 24 hours of collection.

If preparing a platelet concentrate, the platelet-rich plasma should be separated from the red blood cells within 8 hours after collection.

If preparing fresh frozen plasma, separate from the red cells and place in the freezer at -18 °C or colder within 8 hours after blood collection.

For systems with in-line breakaway closure (BAC), use oval style centrifuge cups.

Increased (mechanical) hemolysis has been associated with stripping when blood is cold and has a higher hematocrit. Do not strip forcefully or frequently against a snap-open closure if re-suspension of segmented tubing is necessary.

No adverse reactions specifically attributable to this drug have been reported.

×

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

×

Review

Rate this treatment and share your opinion


Learn about User Reviews

Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

Effectiveness (required)

This medication has worked for me.




Ease of Use (required)

This medication has been easy for me to use.




Satisfaction (required)

Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
×

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
×

Tips

Tips

×

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).